News & Updates

Management of metastatic hormone-sensitive prostate cancer (mHSPC) continues to evolve as clinicians refine the use of androgen deprivation therapy (ADT) and/or chemotherapy in combination with androgen receptor pathway inhibitors (ARPIs) in routine clinical practice. At an advisory board meeting organized by the Hong Kong Society of Uro-Oncology, Professor Axel Merseburger of the University of Lübeck in Germany and Dr Darren Poon of the Hong Kong Sanatorium & Hospital discussed updated strategies and shared case studies to illustrate use of optimal ARPI-based regimens in patients with mHSPC.

Esketamine is more cost-effective than transcranial magnetic stimulation (rTMS) and electroconvul­sive therapy (ECT), but not when compared with other commonly used third-line treatments for treatment-resistant depression (TRD) in Hong Kong, a multi-armed modelling study has shown.